Biohorizon already has a good share of the market for implants.
Striate is replacing an existing product they sell that has little competitive advantage against other products in the market
Striate will give this advantage so they will be able to increase their market share
Replacing the existing product they sell gives Orthocell orders plus the upside growth
Ann: First orders for Striate and Remplir, page-19
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.5¢ |
Change
0.005(0.82%) |
Mkt cap ! $147.0M | |||
| Open | High | Low | Value | Volume |
| 61.5¢ | 62.0¢ | 61.0¢ | $428.7K | 696.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 142386 | 61.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.0¢ | 36604 | 1 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| OCC (ASX) Chart |